Skip to main content
. 2017 Feb 16;112(3):224–235. doi: 10.1590/0074-02760160334

Geographical differences in the proportion of patients who reached the primary endpoint in the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. HR = hazard ratio.

Geographical differences in the proportion of patients who reached the primary endpoint in the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. HR = hazard ratio.